Northland Securities Reaffirms “Buy” Rating for Evgen Pharma PLC (EVG)
Northland Securities restated their buy rating on shares of Evgen Pharma PLC (LON:EVG) in a research report report published on Wednesday morning. They currently have a GBX 97 ($1.26) price target on the stock.
Shares of Evgen Pharma PLC (LON:EVG) opened at 21.50 on Wednesday. The company’s market capitalization is GBX 15.75 million. The stock’s 50 day moving average price is GBX 18.16 and its 200-day moving average price is GBX 20.58. Evgen Pharma PLC has a 1-year low of GBX 13.00 and a 1-year high of GBX 35.00.
Evgen Pharma PLC Company Profile
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane.
Receive News & Ratings for Evgen Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.